We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-25.6%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$585M
AUM Growth
-$238M
Cap. Flow
-$19.6M
Cap. Flow %
-3.35%
Top 10 Hldgs %
58.39%
Holding
39
New
3
Increased
9
Reduced
8
Closed
8

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$13.8M
2
BLUE
bluebird bio
BLUE
+$8.53M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.16M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.54M
5
IBB icon
iShares Biotechnology ETF
IBB
+$6.37M

Top Sells

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$11.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$9.76M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$8.32M
4
OSUR icon
OraSure Technologies
OSUR
+$8.11M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$6.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$50.4M 8.63%
360,000
– –
MYOK
2
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$38.6M 6.6%
790,000
-15,000
-2% -$826K
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$34.5M 5.9%
640,000
-110,000
-15% -$6.69M
CDXS icon
4
Codexis
CDXS
$157M
$33.8M 5.79%
2,025,000
– –
ONCE
5
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$32.9M 5.62%
840,000
+165,000
+24% +$7.16M
BLUE
6
DELISTED
bluebird bio
BLUE
$32.7M 5.6%
25,476
+5,558
+28% +$8.53M
FATE icon
7
Fate Therapeutics
FATE
$289M
$32.7M 5.6%
2,550,000
– –
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$29.9M 5.11%
312,000
– –
BLFS icon
9
BioLife Solutions
BLFS
$1.57B
$29.2M 5%
2,428,571
– –
NVTA
10
DELISTED
Invitae Corporation
NVTA
$26.5M 4.54%
2,400,000
– –
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$29.5B
$25.9M 4.43%
355,000
+85,000
+31% +$6.54M
AGIO icon
12
Agios Pharmaceuticals
AGIO
$1.82B
$20.5M 3.51%
445,000
-134,776
-23% -$8.32M
GNMK
13
DELISTED
GenMark Diagnostics, Inc
GNMK
$18.5M 3.17%
3,815,000
+315,000
+9% +$1.64M
BOLD
14
DELISTED
Audentes Therapeutics, Inc
BOLD
$18.3M 3.14%
860,000
+235,000
+38% +$6.06M
ILMN icon
15
Illumina
ILMN
$30B
$18M 3.08%
61,680
-11,822
-16% -$3.66M
SRPT icon
16
Sarepta Therapeutics
SRPT
$1.68B
$16.4M 2.8%
150,000
+110,000
+275% +$13.8M
DNTH icon
17
Dianthus Therapeutics
DNTH
$5.79B
$15.1M 2.58%
165,207
+24,531
+17% +$3.34M
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
$14.4M 2.46%
350,000
-90,000
-20% -$3.37M
SGMO
19
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$12.4M 2.12%
1,080,000
-920,000
-46% -$11.4M
GRTS
20
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$11.1M 1.9%
720,586
– –
EVH icon
21
Evolent Health
EVH
$353M
$11M 1.88%
550,000
– –
EDIT icon
22
Editas Medicine
EDIT
$404M
$10.9M 1.87%
480,000
+20,000
+4% +$544K
VYGR icon
23
Voyager Therapeutics
VYGR
$181M
$10.6M 1.81%
1,128,075
-6,925
-0.6% -$88.9K
ONC
24
BeOne Medicines Ltd
ONC
$32.6B
$9.82M 1.68%
70,000
– –
QTTB icon
25
Q32 Bio
QTTB
$449M
$7.83M 1.34%
19,444
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return

Casdin Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Casdin Capital held 39 positions worth $585M, down 29% from $823M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Casdin Capital withdrew a net $19.6M in Q4 2018, closing 8 positions and reducing 8 holdings. Its most notable exit was CRISPR Therapeutics, an estimated $9.76M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier.

Against the trend, Casdin Capital opened a new position in iShares Biotechnology ETF worth $5.79M.

  • Casdin Capital's largest Q4 2018 buy was iShares Biotechnology ETF: 60,000 shares worth $5.79M.
  • Casdin Capital added most to Sarepta Therapeutics in Q4 2018, an estimated $13.8M increase.
  • Casdin Capital's biggest Q4 2018 reduction was SANGAMO THERAPEUTICS INC, cutting an estimated $11.4M.
  • Casdin Capital fully exited CRISPR Therapeutics in Q4 2018, selling an estimated $9.76M.
  • Casdin Capital's ten largest holdings make up 58% of its $585M portfolio in Q4 2018.
  • Casdin Capital opened 3 new positions and closed 8 in Q4 2018.
  • Casdin Capital's portfolio value fell 29% quarter-over-quarter to $585M.

Based on Casdin Capital's 13F filing for Q4 2018, filed 13 Feb 2019.